NRx Pharmaceuticals, HOPE Therapeutics sign binding LOI with Neurospa

HOPE Therapeutics, wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a binding Letter of Intent, LOI, to acquire a majority interest in Neurospa TMS Holdings. Neurospa operates six interventional psychiatry clinics on Florida’s Gulf Coast and will constitute a key element of HOPE’s Florida network going forward. Neurospa is revenue generating and EBITDA positive. Neurospa leverages state-of-the-art interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation, and Spravato, augmented by traditional psychiatry and talk therapy to provide a full continuum of care for people with depression, suicidality, PTSD, anxiety, and related disorders.